These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29969826)

  • 41. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
    Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation.
    De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Precisi A; Campani D; Marchetti P; Filipponi F
    Transplant Proc; 2018 Dec; 50(10):3615-3620. PubMed ID: 30577246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
    Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y; Danguilan R; Casasola C; Chang SS; Ruangkanchanasetr P; Kee T; Wong HS; Kenmochi T; Amante AJ; Shu KH; Ingsathit A; Bernhardt P; Hernandez-Gutierrez MP; Han DJ; Kim MS
    Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
    J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.
    Saliba F; De Simone P; Nevens F; De Carlis L; Metselaar HJ; Beckebaum S; Jonas S; Sudan D; Fischer L; Duvoux C; Chavin KD; Koneru B; Huang MA; Chapman WC; Foltys D; Dong G; Lopez PM; Fung J; Junge G;
    Am J Transplant; 2013 Jul; 13(7):1734-45. PubMed ID: 23714399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P; Felipe C; Ferreira A; Cristelli M; Viana L; Mansur J; Basso G; Hannun P; Aguiar W; Tedesco Silva H; Medina-Pestana J
    Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
    Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation.
    Sageshima J; Ciancio G; Chen L; Dohi T; El-Hinnawi A; Paloyo S; Misawa R; Ekwenna O; Yatawatta A; Burke GW
    Clin Transplant; 2014 Jul; 28(7):797-801. PubMed ID: 24779669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
    Saliba F; Fischer L; de Simone P; Bernhardt P; Bader G; Fung J
    Ann Transplant; 2018 Oct; 23():751-757. PubMed ID: 30361470
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
    Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.